DRMA Profile
Dermata Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to the discovery, development, and commercialization of pharmaceutical solutions for both medical and aesthetic skin conditions. The company's primary focus is on advancing treatments for a range of dermatological issues through its innovative product candidates. Dermata’s lead product, DMT310, has completed a Phase IIb clinical trial targeting moderate-to-severe acne and has also undergone a Phase Ib proof-of-concept trial for mild-to-moderate psoriasis. Additionally, DMT310 is currently in a Phase 2 clinical trial for moderate-to-severe rosacea.
Dermata is also progressing the development of DMT410, which has finished Phase Ib proof-of-concept trials for hyperhidrosis, a condition characterized by excessive sweating, as well as for certain aesthetic conditions. This product candidate is part of Dermata's broader strategy to address both functional and cosmetic dermatological needs through advanced therapeutics.
Founded in 2014 and based in San Diego, California, Dermata Therapeutics has positioned itself at the forefront of dermatological innovation. The company's research and development efforts are focused on delivering transformative treatments that can significantly improve patient outcomes and quality of life.
Dermata Therapeutics continues to build on its strong clinical foundation with ongoing trials and development programs aimed at expanding its portfolio. The company's commitment to addressing unmet needs in dermatology underscores its role in advancing therapeutic options for a variety of skin-related conditions.
|
